Feasibility Analysis of Multi-indication Drug Insurance Access and Pricing Strategy in China
- VernacularTitle:我国多适应证药物医保准入和定价策略可行性分析
- Author:
Yuyan FU
1
;
Meif-Eng WANG
;
Wendi CHENG
;
Xiaoxiao TAN
;
Haiyin WANG
Author Information
1. 上海市卫生和健康发展研究中心(上海市医学科学技术情报研究所) 上海 201199
- Keywords:
multi-indication drug;
national reimbursement drug list access;
national reimbursement drug list pricing;
feasibility analysis
- From:
Chinese Health Economics
2024;43(2):29-33
- CountryChina
- Language:Chinese
-
Abstract:
Objective:On the basis of summarizing the previous studies on the access and pricing strategies of multi-indication drugs,based on the actual situation in China,it develops the access and pricing strategies of multi-indication drugs applicable to the adjustment mechanism of China's health insurance catalog and carry out feasibility analysis,with a view to providing methodological support for the national health insurance department in the adjustment of the health insurance catalog in the future.Methods:First,through literature review and expert survey,it sorts out the medical insurance access and pricing strategies for multi-indication drugs that may be applicable in China.Secondly,a feasibility evaluation framework for National Drug Insurance List(NRDL)access and pricing strategies for multi-indication drugs is constructed through literature review,and various stakeholders in the NRDL process are invited to conduct feasibility scores based on the questionnaire.In addition,9 pathways are identified through expert research,and various stakeholders in NRDL process are invited to conduct path analysis based on questionnaires.Finally,relevant recommendations are formed based on the research results.Results:According to the results of the feasibility evaluation the direct access is less feasi-ble,while negotiated access and simplified negotiated access are comparable;pricing by weighted average was less feasible,pricing by primary indication and pricing by minimum value are comparable.The results of the pathway analysis show that differences in health insurance access and pricing strategies for selecting drugs with multiple indications under different pathways.Conclusion:It is needed to refine the medical insurance access and price calculation methods for drugs with multiple indications;improve the database construction to support refined calculation of medical insurance;and actively explore the innovative payment methods for medical insurance with multiple indications.
